Biocon Ltd. is a holding company, which engages in the manufacture, research, and development of therapeutic drugs. It operates through the following segments: Small Molecules, Biologics, Branded Formulations, and Research Services. The Small Molecules segment manufactures spanning statins, immunosuppressants, antifungals, anti-obesity, anti-diabetics, ophthalmologicals, oncologicals, and urologicals etc. The Biologics segment provides Insulins and Analogs, biosimilar Monoclonal Antibodies (MAbs), and recombinant proteins The Branded Formulation segment consists of therapeutic areas of diabetology, oncology, immunology and critical care. The Research Services segment covers Syngene development platforms. The company was founded by Kiran Mazumdar-Shaw on November 29, 1978 and is headquartered in Bangalore, India.
BIOCON LIMITED. financial statements, including revenue, expenses, and profit: The total revenue of BIOCON for the last quarter is 44.17 B INR, and it's 15.59% higher compared to the previous quarter. The net income of Q4 24 is 3.44 B INR.
BIOCON LIMITED. dividends overview: BIOCON dividends are paid annually. The last dividend per share was 0.50 INR. As of today, Dividend Yield (TTM)% is 0.13%.
BIOCON LIMITED. earnings per share and revenue: BIOCON earnings per share for the last quarter are 2.81 INR whereas the estimation was 1.39 INR which accounts for 102.25% surprise. Company revenue for the same period amounts to 44.17 B INR despite the estimated figure of 40.99 B INR. Estimated earnings per share for the next quarter are 0.71 INR, and revenue is expected to reach 39.78 B INR. Also watch annual changes over time to get a bigger picture of BIOCON earnings per share and revenue dynamics.
BIOCON LIMITED. revenue breakdown overview: BIOCON LIMITED. revenue for the last year amounted to 152.62 B INR, the most of which — 89.29 B INR — came from its highest performing source at the moment, Biosimilars, the year earlier bringing 88.18 B INR. The greatest contribution to the revenue figure was made by United States — last year it brought BIOCON LIMITED. 70.42 B INR, and the year before that — 64.55 B INR.
Potential 50% Upside with Entry Price 350 Target Price 525, Timeframe 6-12 Months
Comments
Post a Comment